Ajinomoto Bio-Pharma Services vs Curia (RNA/Advanced): CDMO Comparison
How does Ajinomoto Bio-Pharma Services compare to Curia (RNA/Advanced)?
As of Oct 2026, Ajinomoto Bio-Pharma Services: no FDA inspections on file, 1 EMA/MHRA GMP certificate. Signal Score 83.5. Curia (RNA/Advanced): 2 FDA inspections (including 1 NAI, 1 VAI and 0 OAI), 18 EMA/MHRA GMP certificates. Signal Score 79.5. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of Ajinomoto Bio-Pharma Services and Curia (RNA/Advanced) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Curia (RNA/Advanced) has FDA inspections on record (2); Ajinomoto Bio-Pharma Services does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Curia (RNA/Advanced) holds 18 active EMA GMP certificates; Ajinomoto Bio-Pharma Services does not appear in EudraGMDP.
- Ajinomoto Bio-Pharma Services maintains 1 MHRA / UK GMP certificate; Curia (RNA/Advanced) does not.
Across the cross-modality scorecard, Ajinomoto Bio-Pharma Services carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: Ajinomoto Bio-Pharma Services vs Curia (RNA/Advanced)
How does Ajinomoto Bio-Pharma Services compare to Curia (RNA/Advanced)?
On CDMO Signal's composite Signal Score, Ajinomoto Bio-Pharma Services is 84/100 and Curia (RNA/Advanced) is 80/100; Ajinomoto Bio-Pharma Services has 0 FDA inspections on record vs 2 for Curia (RNA/Advanced); European coverage is 1 active EMA+MHRA certificate for Ajinomoto Bio-Pharma Services vs 18 for Curia (RNA/Advanced). Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Ajinomoto Bio-Pharma Services or Curia (RNA/Advanced)?
Both Ajinomoto Bio-Pharma Services and Curia (RNA/Advanced) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Ajinomoto Bio-Pharma Services has 0 FDA inspections on record; Curia (RNA/Advanced) has 2.
How do Ajinomoto Bio-Pharma Services and Curia (RNA/Advanced) compare on European GMP coverage?
Ajinomoto Bio-Pharma Services holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Curia (RNA/Advanced) holds 18 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
What does the Signal Score gap mean in practice?
Ajinomoto Bio-Pharma Services carries a Signal Score of 84/100 and Curia (RNA/Advanced) carries 80/100 — essentially tied for Ajinomoto Bio-Pharma Services. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →